Pfizer Files 8K - Other Events

Pfizer Inc. (PFE) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 22, 2016.

On August 22, 2016, Pfizer and Medivation issued a press release announcing entry into the Merger Agreement, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser will commence the Offer to acquire all of the outstanding shares of common stock of Medivation at a price of $81.50 per share, net to the seller in cash, without interest, subject to any required withholding of taxes. The Merger Agreement further provides that, upon the terms and subject to the conditions thereof, following completion of the Offer, Purchaser will be merged with and into Medivation, with Medivation surviving the merger as a wholly owned subsidiary of Pfizer, pursuant to the procedure provided for under Section 251(h) of the Delaware General Corporation Law without any additional stockholder approvals.

The Merger is subject to customary regulatory approvals and closing conditions and is expected to close in the Third- or Fourth- Quarter 2016. Pfizer anticipates financing the transaction through existing cash.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000119312516686937/d57934d8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000119312516686937/0001193125-16-686937-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

(END) Dow Jones Newswires

August 22, 2016 08:27 ET (12:27 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.